FAQ on Lantern Pharma Inc. (NASDAQ: LTRN) and Its AI-Driven Oncology Drug Development

What is Lantern Pharma Inc.?

Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages artificial intelligence and machine learning to transform the development of precision cancer therapies.

What is the RADR® platform?

RADR® (Response Algorithm for Drug Positioning & Rescue) is Lantern Pharma’s proprietary AI and machine learning platform that integrates over 200 billion oncology-specific data points to accelerate the development of precision cancer therapies.

What types of cancer is Lantern Pharma targeting?

Lantern Pharma is targeting major oncology markets including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), non-Hodgkin’s lymphoma (NHL), and brain and CNS cancers, including pediatric indications.

What FDA designations has Lantern Pharma received?

Lantern Pharma has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways for its therapies.

How does Lantern Pharma’s approach compare to traditional drug development?

Lantern Pharma’s AI-driven approach has accelerated drug development from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program, significantly reducing the time and cost compared to traditional methods.

Who can benefit from Lantern Pharma’s therapies?

Patients with specific types of cancer, including those with solid tumors and blood cancers, can benefit from Lantern Pharma’s precision oncology therapies, especially those in major oncology markets and rare pediatric indications.

Where can I find more information about Lantern Pharma Inc.?

More information about Lantern Pharma Inc. is available in the company’s newsroom at https://ibn.fm/LTRN and through its profile on the Investor Brand Network.

What is the significance of Lantern Pharma’s work?

Lantern Pharma’s work is significant because it represents a transformative approach to oncology drug development, using AI to reduce costs, accelerate timelines, and improve the precision of cancer therapies.